 Ashley Frazer-Abel
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 14 | 2022 | 327 | 3.770 |
Why?
| | Complement Activation | 12 | 2025 | 415 | 1.240 |
Why?
| | Laboratories | 3 | 2024 | 113 | 1.030 |
Why?
| | Immunoassay | 2 | 2021 | 115 | 0.730 |
Why?
| | Clinical Laboratory Techniques | 2 | 2018 | 97 | 0.640 |
Why?
| | Complement Factor B | 5 | 2025 | 109 | 0.620 |
Why?
| | Laboratories, Hospital | 1 | 2018 | 15 | 0.590 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 99 | 0.560 |
Why?
| | RNA, Transfer | 3 | 2008 | 138 | 0.520 |
Why?
| | Angioedemas, Hereditary | 2 | 2014 | 4 | 0.480 |
Why?
| | Macular Degeneration | 3 | 2022 | 164 | 0.450 |
Why?
| | RNA | 3 | 2008 | 921 | 0.420 |
Why?
| | Autoimmune Diseases | 4 | 2022 | 460 | 0.400 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 804 | 0.390 |
Why?
| | Anticodon | 3 | 2004 | 24 | 0.390 |
Why?
| | Nucleic Acid Conformation | 4 | 2008 | 728 | 0.390 |
Why?
| | Wet Macular Degeneration | 2 | 2025 | 56 | 0.370 |
Why?
| | Geographic Atrophy | 2 | 2025 | 79 | 0.370 |
Why?
| | Angioedema | 1 | 2011 | 16 | 0.360 |
Why?
| | Anti-Citrullinated Protein Antibodies | 3 | 2021 | 115 | 0.350 |
Why?
| | Emergency Responders | 2 | 2021 | 36 | 0.340 |
Why?
| | Oligonucleotides, Antisense | 2 | 2025 | 112 | 0.330 |
Why?
| | Immunologic Tests | 2 | 2021 | 16 | 0.320 |
Why?
| | Cyclin-Dependent Kinase 4 | 3 | 2006 | 47 | 0.310 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 189 | 0.310 |
Why?
| | Autoantibodies | 3 | 2021 | 1496 | 0.300 |
Why?
| | T-Lymphocytes | 3 | 2009 | 1996 | 0.300 |
Why?
| | Specimen Handling | 2 | 2022 | 183 | 0.300 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2019 | 132 | 0.300 |
Why?
| | Humans | 50 | 2025 | 137585 | 0.290 |
Why?
| | Arthritis, Rheumatoid | 3 | 2021 | 1167 | 0.260 |
Why?
| | Kidney Diseases | 2 | 2021 | 408 | 0.260 |
Why?
| | Tars | 1 | 2006 | 5 | 0.250 |
Why?
| | Smoking | 3 | 2019 | 1627 | 0.250 |
Why?
| | Complement Factor H | 2 | 2019 | 80 | 0.250 |
Why?
| | Nicotine | 2 | 2009 | 334 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 42 | 0.250 |
Why?
| | Complement Pathway, Alternative | 2 | 2025 | 122 | 0.240 |
Why?
| | Thionucleotides | 1 | 2025 | 35 | 0.230 |
Why?
| | Complement C3a | 3 | 2019 | 42 | 0.230 |
Why?
| | RNA, Transfer, Ser | 2 | 2008 | 4 | 0.230 |
Why?
| | Cell Cycle | 2 | 2006 | 601 | 0.230 |
Why?
| | B-Cell Activating Factor | 1 | 2024 | 21 | 0.230 |
Why?
| | Complement Factor D | 1 | 2024 | 30 | 0.220 |
Why?
| | Nuclear Proteins | 3 | 2004 | 712 | 0.210 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 73 | 0.210 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2023 | 22 | 0.210 |
Why?
| | Scleroderma, Systemic | 1 | 2024 | 122 | 0.210 |
Why?
| | Quality Control | 2 | 2021 | 172 | 0.210 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 23 | 0.200 |
Why?
| | Vitreous Body | 2 | 2022 | 110 | 0.200 |
Why?
| | Disease Susceptibility | 4 | 2020 | 347 | 0.200 |
Why?
| | Trichloroethylene | 1 | 2022 | 8 | 0.190 |
Why?
| | Protein Aggregates | 2 | 2019 | 72 | 0.190 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 30 | 0.180 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 132 | 0.180 |
Why?
| | Complement Inactivator Proteins | 1 | 2021 | 42 | 0.180 |
Why?
| | Extracellular Traps | 1 | 2021 | 53 | 0.180 |
Why?
| | Cross Reactions | 1 | 2021 | 133 | 0.180 |
Why?
| | Reference Standards | 1 | 2021 | 186 | 0.170 |
Why?
| | Immunologic Factors | 2 | 2022 | 236 | 0.170 |
Why?
| | Europe | 2 | 2020 | 414 | 0.170 |
Why?
| | Retinal Drusen | 1 | 2021 | 31 | 0.170 |
Why?
| | Magnesium | 4 | 2008 | 156 | 0.170 |
Why?
| | DNA-Binding Proteins | 3 | 2004 | 1502 | 0.160 |
Why?
| | Transcription Factors | 4 | 2004 | 1719 | 0.160 |
Why?
| | Sputum | 1 | 2021 | 311 | 0.160 |
Why?
| | Polyvinyl Chloride | 1 | 2019 | 9 | 0.160 |
Why?
| | Diethylhexyl Phthalate | 1 | 2019 | 15 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 39 | 0.150 |
Why?
| | Complement C3 | 2 | 2019 | 209 | 0.150 |
Why?
| | Biomarkers | 4 | 2024 | 4149 | 0.150 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 377 | 0.150 |
Why?
| | Biological Products | 1 | 2022 | 216 | 0.150 |
Why?
| | Rheumatoid Factor | 1 | 2019 | 175 | 0.150 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.150 |
Why?
| | Occupational Exposure | 1 | 2022 | 341 | 0.140 |
Why?
| | Mitochondria, Heart | 1 | 1999 | 102 | 0.140 |
Why?
| | Mass Spectrometry | 1 | 2021 | 739 | 0.140 |
Why?
| | Complement Inactivating Agents | 1 | 2017 | 63 | 0.130 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 81 | 0.130 |
Why?
| | Complement C3 Nephritic Factor | 1 | 2016 | 1 | 0.130 |
Why?
| | Complement C5 | 1 | 2016 | 81 | 0.130 |
Why?
| | Inflammation | 4 | 2021 | 2837 | 0.130 |
Why?
| | Riboflavin | 1 | 2016 | 13 | 0.120 |
Why?
| | Virus Inactivation | 1 | 2016 | 13 | 0.120 |
Why?
| | Ebolavirus | 1 | 2016 | 35 | 0.120 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2016 | 36 | 0.120 |
Why?
| | Blood | 1 | 2016 | 107 | 0.120 |
Why?
| | Critical Illness | 1 | 2021 | 811 | 0.120 |
Why?
| | Base Sequence | 4 | 2008 | 2181 | 0.120 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2015 | 47 | 0.120 |
Why?
| | RNA, Fungal | 3 | 2008 | 72 | 0.120 |
Why?
| | Animals | 11 | 2022 | 36940 | 0.110 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2014 | 11 | 0.110 |
Why?
| | RNA, Transfer, Phe | 2 | 2008 | 9 | 0.110 |
Why?
| | Male | 18 | 2025 | 67762 | 0.110 |
Why?
| | Oligoribonucleotides | 1 | 2014 | 52 | 0.110 |
Why?
| | Disinfection | 1 | 2016 | 124 | 0.110 |
Why?
| | Female | 19 | 2025 | 73304 | 0.110 |
Why?
| | Autoimmunity | 1 | 2020 | 908 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 3 | 2004 | 648 | 0.110 |
Why?
| | Birefringence | 3 | 2004 | 6 | 0.110 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 345 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 815 | 0.100 |
Why?
| | Disease Progression | 4 | 2025 | 2757 | 0.100 |
Why?
| | Nanoparticles | 1 | 2019 | 481 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1040 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 396 | 0.100 |
Why?
| | Antibodies, Viral | 3 | 2022 | 625 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2012 | 28 | 0.100 |
Why?
| | Comprehension | 1 | 2014 | 172 | 0.100 |
Why?
| | Aged | 9 | 2025 | 23961 | 0.100 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 132 | 0.100 |
Why?
| | Middle Aged | 11 | 2025 | 33479 | 0.100 |
Why?
| | Molecular Sequence Data | 5 | 2014 | 2900 | 0.100 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2011 | 6 | 0.090 |
Why?
| | Cattle | 2 | 2008 | 984 | 0.090 |
Why?
| | Complement C4 | 1 | 2011 | 28 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2189 | 0.090 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 213 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 165 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2020 | 3556 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7635 | 0.080 |
Why?
| | Oligonucleotides | 2 | 2014 | 148 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2012 | 513 | 0.080 |
Why?
| | Mutation | 2 | 2020 | 3958 | 0.080 |
Why?
| | Complement C5a | 2 | 2019 | 71 | 0.080 |
Why?
| | Drug Packaging | 2 | 2019 | 45 | 0.080 |
Why?
| | Risk Factors | 4 | 2025 | 10388 | 0.080 |
Why?
| | Nicotinic Agonists | 1 | 2009 | 129 | 0.070 |
Why?
| | Particle Size | 2 | 2019 | 394 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 183 | 0.070 |
Why?
| | Adult | 9 | 2025 | 37929 | 0.070 |
Why?
| | Phenotype | 3 | 2022 | 3196 | 0.070 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 363 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2006 | 4193 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1483 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2022 | 893 | 0.070 |
Why?
| | NFATC Transcription Factors | 2 | 2004 | 95 | 0.070 |
Why?
| | Lymphocyte Activation | 2 | 2012 | 1142 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3715 | 0.060 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2006 | 15 | 0.060 |
Why?
| | Cell Survival | 1 | 2009 | 1120 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 90 | 0.060 |
Why?
| | G1 Phase | 1 | 2006 | 71 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2025 | 1993 | 0.060 |
Why?
| | Macaca fascicularis | 2 | 2016 | 65 | 0.060 |
Why?
| | Temperature | 1 | 2008 | 679 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 99 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 852 | 0.060 |
Why?
| | Hemangiosarcoma | 1 | 2004 | 21 | 0.050 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2004 | 92 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5131 | 0.050 |
Why?
| | Plasmids | 1 | 2004 | 363 | 0.050 |
Why?
| | Dog Diseases | 1 | 2004 | 64 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 104 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 301 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 34 | 0.050 |
Why?
| | Antibodies, Antinuclear | 1 | 2022 | 71 | 0.050 |
Why?
| | Time Factors | 2 | 2025 | 6828 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 114 | 0.050 |
Why?
| | Cytokines | 2 | 2012 | 2085 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 123 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 168 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2024 | 530 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 137 | 0.040 |
Why?
| | United States | 1 | 2018 | 14841 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2002 | 2607 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 329 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4565 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 109 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2004 | 2833 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 545 | 0.040 |
Why?
| | Apoptosis | 1 | 2009 | 2553 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 289 | 0.040 |
Why?
| | RNA, Bacterial | 1 | 2001 | 190 | 0.040 |
Why?
| | Vitrectomy | 1 | 2020 | 70 | 0.040 |
Why?
| | Complement C4a | 1 | 2019 | 9 | 0.040 |
Why?
| | Plasticizers | 1 | 2019 | 15 | 0.040 |
Why?
| | Freezing | 1 | 2019 | 90 | 0.040 |
Why?
| | Syringes | 1 | 2019 | 44 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 101 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 53 | 0.040 |
Why?
| | South Carolina | 1 | 2019 | 38 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 132 | 0.040 |
Why?
| | Cations, Divalent | 1 | 1999 | 52 | 0.040 |
Why?
| | Drug Stability | 1 | 2019 | 167 | 0.040 |
Why?
| | Rheology | 1 | 2019 | 92 | 0.040 |
Why?
| | Yeasts | 1 | 1999 | 53 | 0.040 |
Why?
| | Protein Stability | 1 | 2019 | 176 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 151 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2475 | 0.040 |
Why?
| | Calcium | 1 | 2004 | 1199 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 413 | 0.040 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 38 | 0.040 |
Why?
| | Young Adult | 3 | 2025 | 13209 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 138 | 0.040 |
Why?
| | Complement Pathway, Classical | 1 | 2017 | 20 | 0.030 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 20 | 0.030 |
Why?
| | HIV Infections | 1 | 2012 | 2836 | 0.030 |
Why?
| | Body Mass Index | 2 | 2019 | 2389 | 0.030 |
Why?
| | Prolactin | 1 | 1997 | 96 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2019 | 485 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 87 | 0.030 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 26 | 0.030 |
Why?
| | Mice | 3 | 2022 | 17787 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 1250 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 496 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1276 | 0.030 |
Why?
| | Epitopes | 1 | 2019 | 479 | 0.030 |
Why?
| | Escherichia coli | 1 | 2001 | 815 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 460 | 0.030 |
Why?
| | Jurkat Cells | 2 | 2009 | 134 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 1997 | 172 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1070 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2828 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 570 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 628 | 0.030 |
Why?
| | Vero Cells | 1 | 2016 | 69 | 0.030 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 827 | 0.030 |
Why?
| | Adolescent | 4 | 2016 | 21513 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 820 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2017 | 242 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2020 | 766 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2844 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 15657 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 411 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2014 | 2139 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 322 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1502 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 1997 | 324 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1468 | 0.030 |
Why?
| | Signal Transduction | 3 | 2009 | 5079 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 2074 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 322 | 0.030 |
Why?
| | Child | 3 | 2021 | 21935 | 0.030 |
Why?
| | Binding Sites | 3 | 2002 | 1303 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1997 | 405 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2024 | 1910 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2012 | 22 | 0.020 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 11 | 0.020 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 19 | 0.020 |
Why?
| | Raltegravir Potassium | 1 | 2012 | 17 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 27 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2012 | 43 | 0.020 |
Why?
| | Insulin | 1 | 2023 | 2409 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 49 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1724 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.020 |
Why?
| | Cell Division | 2 | 2004 | 794 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3295 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 271 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5472 | 0.020 |
Why?
| | Viral Load | 1 | 2012 | 466 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2012 | 353 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2057 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 2009 | 4 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 215 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7604 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1704 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 635 | 0.020 |
Why?
| | Transfection | 2 | 2002 | 945 | 0.020 |
Why?
| | Receptors, Nicotinic | 1 | 2009 | 334 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1710 | 0.020 |
Why?
| | HIV-1 | 1 | 2012 | 864 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1091 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 900 | 0.020 |
Why?
| | Ploidies | 1 | 2004 | 18 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2004 | 164 | 0.010 |
Why?
| | Protein Binding | 2 | 2001 | 2224 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2002 | 100 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 413 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2004 | 466 | 0.010 |
Why?
| | Luciferases | 1 | 2002 | 150 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2002 | 269 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 534 | 0.010 |
Why?
| | Cyclosporine | 1 | 2002 | 268 | 0.010 |
Why?
| | Exons | 1 | 2002 | 355 | 0.010 |
Why?
| | Tacrolimus | 1 | 2002 | 199 | 0.010 |
Why?
| | Base Pairing | 1 | 2001 | 64 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 521 | 0.010 |
Why?
| | Histone Deacetylases | 1 | 2002 | 215 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2002 | 378 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 976 | 0.010 |
Why?
| | Lymphocytes | 1 | 2002 | 397 | 0.010 |
Why?
| | RNA Stability | 1 | 2001 | 117 | 0.010 |
Why?
| | Ribosomes | 1 | 2001 | 186 | 0.010 |
Why?
| | Models, Genetic | 1 | 2002 | 600 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 11074 | 0.010 |
Why?
| | Cell Movement | 1 | 2004 | 967 | 0.010 |
Why?
| | Chromatin | 1 | 2002 | 519 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1997 | 27 | 0.010 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.010 |
Why?
| | Phosphorylation | 1 | 2002 | 1759 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 45 | 0.010 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 1997 | 25 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 56 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 927 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 182 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2002 | 2167 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1997 | 52 | 0.010 |
Why?
| | Coenzymes | 1 | 1997 | 19 | 0.010 |
Why?
| | Catalysis | 1 | 1997 | 307 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1783 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1997 | 123 | 0.010 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 1997 | 72 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 267 | 0.010 |
Why?
| | Mediator Complex | 1 | 1997 | 61 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2004 | 3412 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1570 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1997 | 955 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1997 | 434 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 506 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5647 | 0.000 |
Why?
|
|
Frazer-Abel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|